Answers are grounded in this paper and cite their sources.
ISAT: International Subarachnoid Aneurysm Trial SAH: subarachnoid hemorrhage tPA: tissue plasminogen activator Disruptive innovation is a term that was coined by Dr Clayton Christensen, professor of business at Harvard Business School.1 In this, he describes the process by which a product emerges into an existing market, typically from outside established market leaders, and then relentlessly displaces established competitors. Key components of a disruptive technology include performance characteristics that initially are undervalued due to a failure to meet current demands, but possessing rapid improvement rates which rapidly outpace iterative advances by established technologies. Examples include the personal computer as a disruptor to main frame, cellular phones to fixed-line telephones, community colleges to 4-yr college, and, more recently, retail medical clinics were disruptors to traditional doctor's offices (Figure 1). By any measure, the development of neuroendovascular surgery has been a disruptive technology in the treatment of cerebrovascular disease against the established microvascular techniques.FIGURE 1: Examples of some disruptive technologies and the entrenched competitors they dislodged (left). Graphical representation of the disruptive process, by which a disruptive competitor may enter the market with a lower performance but rapidly displaces leading technologies which can only develop in an iterative manner due to existing market competition (right).The endovascular treatment of cerebral aneurysms in particular has been the major driver of the disruption neurovascular surgery more broadly in the latter part of the 20th century and early part of the 21st century.2 Early adopters of endovascular aneurysm coil embolization were able to leverage the inherent advantages of the endovascular approach (ie, minimally invasive access, avoidance of associated perforating vessels, and improved access to aneurysms that were more difficult to reach by the open route) in order to alter the existing market for aneurysm surgery.3 Of course, traditional microsurgical techniques remain a core component aneurysm surgery (Figure 2). This technology, though initially limited in scope and efficacy, has driven the design of new operating rooms, broader changes in patient management strategies, and is now considered by most to be an essential component of training for new generations of cerebrovascular surgeons. Moreover, disruption in aneurysm treatment has been the driving force behind novel technologies and emerging markets for treatment of acute stroke and other brain disorders by the endovascular route.FIGURE 2: Disruptive endovascular technology has demanded generation of unique skillsets and support staff, training mechanisms, and even physical spaces, such as the neurovascular biplane angiography suite (left). Traditional microsurgery (right) is still a core component of aneurysm treatment, but has had to rapidly adapt to the new normal imposed by disruptive endovascular technology.Evidence-based medicine research practices have typically served as the bulwark against destabilizing hype cycles in medical technology. To this end, the International Subarachnoid Aneurysm Trial (ISAT) was the first major randomized trial to assess the effect of coiling vs clipping in the ruptured aneurysm patient.4 Originally published in 2002, ISAT proved a disruptive event in its own right. While it has spurred a significant amount of debate, the study found that coiling resulted in improved outcomes at 1-yr follow-up compared to clip ligation. Significant methodological problems did diminish the impact of the conclusions from ISAT (such as the failure to randomize an extremely large portion of screened patients).5 However, the core finding of improved outcomes within the first year after subarachnoid hemorrhage for coiled patients has been replicated in several other studies.6-8 While ISAT is the only study that has shown persistence of this effect beyond the 1-yr time point, it served to cement the endovascular approach as the new leader in the market for ruptured aneurysms. In our own institution, 2001 was the last year when more aneurysms were treated via a transcranial approach as opposed to an endovascular approach, and this has had a consistent rise through the years. The prototypical example of the disruptiveness of this therapy is in the treatment of basilar artery aneurysms (Figure 3). The established microsurgical clip ligation therapy is technically demanding and demands dissection of several critical structures. These factors remain unchanged since the clipping technique was pioneered by Charles Drake, but are fundamentally altered by the advent of the endovascular approach. Over a relatively short time period, the overwhelming majority of treatment centers worldwide have adopted a coil-first strategy for this type of patient, the true hallmark of a disruptive technology emerging as the new leader in a field.FIGURE 3: Diagnostic cerebral angiogram of a basilar apex aneurysm (left). This aneurysm, by virtue of its deep location, difficult access, and close association with critical tiny perforating vessels is a challenge for master cerebrovascular surgeons with an open approach, even with the favorable anatomy of this aneurysm. Iterative improvements in microvascular technique failed to address these core problems, but the disruptive approach taken by endovascular coiling (right) has reinvented the standard of care for these aneurysms worldwide.The relatively high rate of recurrence after endovascular therapy does remain, but this limitation is actively being included in the treatment paradigm for aneurysm patients.9 At our institution, patients with subarachnoid hemorrhage (SAH) from aneurysm that cannot be completely coiled without significant risk of patient morbidity are frequently near-totally coiled (without the need for an angiographically perfect result up front if it imparts a greater risk to the patient). We have frequently adopted a strategy that plans for early clip ligation of recurrent ruptured aneurysms, at approximately 6 mo after SAH, if necessary. This takes advantage of the early benefit to coil embolization in the acute phase and pairs it with the durability of clip ligation performed in a much less dangerous setting. Likewise, the disruptive nature of endovascular therapy has driven advances in microsurgery, such as minimally invasive tailored craniotomies, in order to maintain competitiveness. In a similar manner, flow diversion technology has gone on to disrupt now-standard conventions in endovascular therapy. Much of the early emphasis of neuroendovascular therapy was on the endosaccular approach to occlusion. However, novel devices have given interventionalists the capacity to exclude an aneurysm from the circulation by redirecting flow past it, taking advantage of endogenous mechanisms of aneurysmal thrombosis in the setting of slowed flow after stenting. Flow diverting stents have proven particularly useful for large and giant aneurysms of the paraclinoid region, and for those with dysplastic morphologies, for which both microsurgical and traditional stent/coil endovascular approaches have obvious limitations (Figure 4).10FIGURE 4: Giant cavernous internal carotid artery aneurysms presented a significant challenge to both clip and coil techniques. The aneurysm seen at left required multiple coiling retreatments. A similar aneurysm in another patient (center) was referred for flow diversion therapy. Follow-up angiography 6 mo after stent placement (right) shows complete obliteration of the aneurysm and reconstitution of the normal internal carotid artery anatomy.Many of the other studies performed and published from our institution indicate that clearly endovascular therapy has been a disruptive innovator with statistically better outcomes for certain aneurysm locations and neurological grades.11-13 If one looks at the flow diversion for ophthalmic artery aneurysms in particular, the results have been outstanding as the article entitled “Flow-diversion for ophthalmic segment aneurysms”14 illustrates with little or no optic apparatus compromise. Though not a primary treatment for ruptured aneurysms, due to delayed protection and dual-antiplatelet therapy, we have demonstrated that flow diversion can be used safely in this off-label setting when the situation demands as well.15 If we conceive of neuroendovascular surgery as a set of delivery/access techniques, as opposed to a treatment solely for aneurysms, one can understand the cross-fertilization into other arenas that has taken place, such as treatment for retinoblastoma. The ophthalmic artery selective catheterization and intra-arterial chemotherapy delivery has been shown to be very effective in the treatment of retinoblastoma and has in many cases prevented enucleation.16 Likewise, direct access to the superior ophthalmic vein by a transpalpebral approach is a novel method for accessing difficult-to-reach vascular territories. Such advances are representative of satellite disruptive technologies that are predicated on the initial disruption in aneurysm surgery. These approaches are now coming to define a new standard of care. Any discussion of disruptive neurovascular technology would be incomplete without addressing the tremendously disruptive innovation at the heart of contemporary management of ischemic stroke. The introduction of tissue plasminogen activator (tPA) therapy for acute infarction was the first therapy that showed consistent benefit.17 Surgical interventions, such as cerebral bypass surgery, had previously proved woefully lacking.18 The introduction of successive generations of endovascular devices for cerebral thrombectomy has revolutionized treatment of this disease. The current state-of-the-art stentriever devices (also serendipitously discovered as a result of endovascular aneurysm surgery) have routinely been shown to result in substantially improved cerebral revascularization and outcome compared to tPA alone.19 The effect is improved patient selection using physiological imaging to diagnose patients with “at-risk” territory but without completed infarction (Figure 5). This disruption has in turn identified the need for a stroke referral network in order to maximize access to treatment for stroke patients. Telemedicine has been a major disruption in a positive manner in the treatment of acute stroke. In our institution, we have performed over 9000 consults in a 37-hospital network. Due to immediate treatment, 82% of these patients have remained in the community with a 16% overall treatment rate with administration of intravenous tPA compared to the national average in the 3% to 5% range. In 2016, the tPA treatment rate in the Jefferson Neuroscience Network has increased to approximately 19%, with a mean response times of 12 min. Neurosurgeons have become leaders in the treatment of ischemic stroke. We have also achieved joint commission certification for primary stroke in 7 centers without the presence of on-site Neurology or Neurosurgery. Therefore, telemedicine clearly has been a major advance and once again a disruptive innovation in the treatment of ischemic stroke at small- to medium-size hospitals without neurological sophistication.FIGURE 5: A patient presented to our institution with a complete carotid occlusion and hemiparesis, but was not a candidate for tPA due to presentation outside the FDA-approved administration window (left). Computed tomography-perfusion imaging (center) demonstrated the viability of the affected region by means of flow/volume mismatch. Cervical internal carotid artery thrombectomy was performed successfully and the patient made a full recovery (right). Prior to the advent of endovascular thrombectomy, the patient would not have had any surgical revascularization options.As we move forward, the Neurosurgical community is advancing into the treatment of chronic stroke. Our research group is seeking to understand the role of neural stem cells in recovery from stroke, through animal models of endogenous neural stem cell niches in the circumventricular organs.20 Furthermore, we are studying methods to enhance exogenous intra-arterial stem cell infusions after acute stroke combined with functional modulation of blood brain barrier integrity to enhance engraftment.21 These research questions will help form future disruptions in the treatment of ischemic stroke, reaching the large numbers of patients currently ineligible for acute revascularization. Moving forward, we believe that cerebrovascular surgeons are called to lead even when the path forward is least clear: as quoted in the Bible from John 13:36 “‘Lord, whither goest thou?’ and Jesus answered him, ‘Whither I go, thou canst not follow me now; but thou shalt follow me afterwards’.” Disclosure The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.
No takes yet. Share an insight, caveat, or question.
Rosenwasser et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: